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Objective: To confirm syntaxin 1A as a risk factor for
migraine, given that syntaxin 1A interacts with several
factors in migraine pathophysiology.
Design: Case-control approach.
Setting: An outpatient clinic.
Participants: In a sample of 188migraineurs (111with-
out aura and 77 with aura) and 287 migraine-free con-
trols, 3 tagging SNPs of STX1A (rs3793243, rs941298,
and rs6951030)were analyzed. A backward stepwisemul-
tiple logistic regression was performed. Allelic and hap-
lotypic frequencieswere comparedbetween cases and con-
trols.
Results: We found that rs941298 and rs6951030 were
risk factors for migraines. In particular, the TT geno-
type of rs941298 is associated with an increased risk of
bothmigraine in general andmigraine without aura; the
GG and GT genotypes for rs6951030 are also associated
with migraine, while the GT genotype of rs6951030 was
found to be significant in themigrainewithout aura group.
The single-nucleotide polymorphism rs3793243 did not
show any significant association. In the haplotype-
based analysis, we found an underrepresentation of the
T-C-Thaplotype (rs3793243-rs941298-rs6951030) in the
global sample and in migraine without aura group. We
found an enrichment of the G allele of rs6951030 for fe-
male migraineurs only.
Conclusions: We confirmed the involvement of syn-
taxin 1A in migraine susceptibility regarding rs941298.
In addition, we found rs6951030 to also be associated
in Portuguese migraine patients. Sex differences should
be further explored to disentangle a possible sex suscep-
tibility in syntaxin 1A.
Arch Neurol. 2010;67(4):422-427
M IGRAINE IS A COMMONneurological disor-der, affecting about15% of the generalpopulation.1,2 Famil-
ial aggregation studies have shown thatmi-
graine is essentially caused by genetic fac-
tors, with multiple genes contributing to
its liability, in addition to environmental
factors.3We have also confirmed the pres-
ence of a genetic component in migraine
with and without aura in a Portuguese
population.4
Although some loci for migraine with
and without aura have been proposed, the
genes involved have not yet been identi-
fied. Several candidate genes have been
studied, with contradictory results.3 Some
evidence supports that the neurotransmit-
ter system is also involved in migraine
pathophysiology.5 Serotonin plays a role in
painmodulation, and serotonin agonists are
an effective therapeutic approach to mi-
graine.6 The serotonin transporter is in-
volved in serotonin reuptake and is a tar-
get for serotonin reuptake inhibitors.7
Syntaxin 1A is a presynaptic plasma
membrane protein of the syntaxin family
that, in conjunction with other proteins,
compose the soluble N-ethylmaleimide-
sensitive factor attachment protein recep-
tor (SNARE) complex, which is crucial for
the regulation of the presynaptic release of
neurotransmitters. Syntaxin 1A, encoded
by the STX1A gene (OMIM186590), is one
of the regulatory proteins of the expres-
sion and subcellular localizationof the sero-
tonin transporter.7 Furthermore, syntaxin
1A binds to the neuronal -aminobutyric
acid (GABA) transporter, inhibiting its re-
uptake.-Aminobutyric acid is themain in-
hibitory neurotransmitter in the brain, and
some GABA-receptor agonists are used in
migraine prophylaxis.8
Nitric oxide is also involved in the for-
mation of the SNARE complex and in the
interaction of syntaxin 1A and the GABA
transporter.9 Nitric oxide has also been as-
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sociated with the nociception mechanism and conse-
quently with migraine pathophysiology.10
The gene encoding the 1A subunit of a voltage-
dependent calcium channel (CACNA1A) is involved in
a rare form ofmigraine with aura, familial hemiplegicmi-
graine (FHM) type 1. It has been shown that the asso-
ciation of the SNAREproteinswith presynapticCa2 chan-
nels, includingCACNA1A, is essential for neurotransmitter
release.11
Recently, syntaxin 1Awas proposed as a risk factor for
migraine.12 The aim of this study was to confirm the in-
volvement of syntaxin1A inmigraine’s susceptibility, using
a case-control approach, given that syntaxin 1A interacts
with several factors of migraine pathophysiology.
METHODS
SUBJECTS
Onehundred eighty-eight unrelated patientswithmigraine (111
without aura, 77with aura), from theneurology outpatient clinic,
at Hospital de Santo Anto´nio, Porto, Portugal, were sequen-
tially enrolled in this study. Patients with FHM were ex-
cluded;migraineurswith coocurrence ofmigrainewith andwith-
out aura were included in the groupwith aura. Control subjects
(n=287), with no history of migraine, were ascertained among
healthy blood donors and from the obstetrics and gynecology
department of Hospital de Santo Anto´nio. Women with men-
strual headaches were excluded from the control group. Con-
trols were from the same ethnic and geographical origin as the
cases (northern region of the country) and were age-matched.
A diagnostic interview was performed in cases and controls,
based on the operational criteria of the International Head-
ache Society, using the same structured questionnaire. The first
edition of the International Headache Society criteria13 was used
before 2004; when revising the diagnosis using the second edi-
tion,14 we found no differences in patients’ diagnosis (data not
shown). Participants gave their written informed consent, and
the ethics committee of the Hospital de Santo Anto´nio ap-
proved the project.
SELECTION OF SNPs AND GENOTYPING
GenomicDNAwas isolated fromperipheral blood, using a stan-
dard salting out method15 or from saliva, using ORAGENE kits
according to themanufacturer’s instructions (DNAGenotek Inc).
Single-nucleotide polymorphisms (SNPs) were selected based
on a data registry from the International HapMap Project; tag-
ging SNPs were selected using Haploview 4.1, at an r2 thresh-
old of 0.80, with a minor allele frequency greater than 0.10, by
an aggressive tagging approach.16 Tagging SNPs included
rs3793243 (located in chromosome 7: 72 759 283), rs941298
(72 763 199), and rs6951030 (72 771 177, according to the En-
sembl database).
In the first stage, allelic discrimination was performed using
molecular beacons and real-time polymerase chain reactions
(PCRs) (iQ5 Real-Time PCR Detection System, Bio-Rad Labo-
ratories). A few discrepancies were found, however, after se-
quencing (to confirm uncertain genotypes): real-time PCR did
not prove to be a reliablemethod for allelic discrimination with
these SNPs. Therefore, we chose to sequence all samples for
rs3793243 and rs941298, while for rs6951030 we used a re-
striction-enzyme analysis.
All SNPswere PCR-amplified usingHotStar TaqMasterMix
Kit (Qiagen) according to the manufacturer’s instructions
(primer sequences are available from the authors on request).
Sequencing was performed using the Big Dye Terminator Cycle
Sequencing, version 1.1, Ready Reaction (Applied Biosys-
tems), according to themanufacturer’s instructions, and samples
were loaded in an ABI-PRISM 3130 XL genetic analyzer (Ap-
plied Biosystems). Restriction enzyme analysis was performed
with BsrI after PCR amplification, and electrophoresis was per-
formed on digestion products in a 2% agarose gel, stained with
ethidium bromide.
STATISTICAL ANALYSIS
Power estimationswere performedusing theGenetic PowerCal-
culator (http://pngu.mgh.harvard.edu/~purcell/gpc/). Analy-
sis ofHardy-Weinberg equilibriumwas also performed.17 Demo-
graphic data of patients and controls were compared using a
2 test for categorical variables. To compare SNP allele fre-
quencies between cases and controls, the 2 test was used, and
odds ratios (ORs) were estimated with 95% confidence inter-
vals (CIs). Significance was set at =.05.
A backward stepwise multiple logistic regression was per-
formed (with the most frequent homozygote as the reference
category) to evaluate the association between the SNPs’ geno-
types and the occurrence of migraine, by including the 3 SNPs
and sex in the initialmodel.We also evaluated the role of STX1A
in the migraine subtypes. All analyses were performed in the
total sample, as well as in the subsets ofmigrainewith andwith-
out aura. Significance was set at =.016 (considering 3 logis-
tic regressions) using a Bonferroni correction to correct formul-
tiple comparisons.
These analyses were performed using SPSS, version 16.0.
Haplotype frequencies were compared between cases and
controls, using Haploview 4.1 with all parameters set at the de-
fault values.16 Haplotypes were estimated, using an acceler-
ated expectation-maximization algorithmsimilar to the partition-
ligation expectation-maximization algorithm described by Qin
et al,18 and case-control counts were obtained by summing the
fractional likelihoods of each individual for each haplotype.16
Frequencies of analyzed haplotypes were above 1%, according
to the Haploview threshold; to correct for multiple compari-
sons, regarding estimation of allelic and haplotype frequen-
cies, we used 10 000 permutations. In the pooled sample, a 2
and OR were estimated, assuming =.05, to compare allelic
and genotypic frequencies between cases and controls.
RESULTS
We analyzed a sample of 188 unrelated migraineurs and
287 age-matched controls (case to control ratio of 1:1.5).
With this sample, we had a power of 64% to detect as-
sociation (for a nominal =.05), assuming a high-risk
allele frequency of 0.1, a relative risk for AA genotype of
2.25, and 1.5 for Aa genotype. A migraine prevalence of
16%had been previously estimated in a Portuguese popu-
lation.19,20
Demographic and clinical data can be found in
Table1. A family history ofmigraine was present in 87%
of the cases. No significant differences were found re-
garding sex between patients and controls (P .05).
Both case and control groups were in Hardy-
Weinberg equilibrium for the 3 SNPs studied. The cor-
relation between the 3 SNPswas small, denoting theweak
linkage disequilibrium (LD) between them according to
the LD plot (Figure). In our sample, the 3 SNPs were
also in weak LD (data not shown).
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Regarding allele frequencies (Table 2), we found an
enrichment of the G allele of rs6951030 among mi-
graineurs (OR, 1.52; 95% CI, 1.12-2.06) as well as in
the group without and the group with aura (without
aura, OR, 1.48; 95% CI, 1.04-2.12; with aura, OR, 1.58;
95% CI, 1.06-2.36); however, after permutation-based
correction, the result for migraine without aura and
with aura did not reach significance. We found an en-
richment of the T allele for rs941298 in patients with
migraines without aura (OR, 1.44; 95% CI, 1.04-1.99);
however, this finding did not hold after permutation-
based correction. No significant differences were found
for this SNP in the other groups. There were no signifi-
cant differences in the allele frequencies between cases
and controls, regarding rs3793243, for any of the
groups.
Additionally, we stratified these data by sex and found
an enrichment of the G allele of rs6951030 only in fe-
malemigraineurs (OR, 1.56; 95%CI: 1.11-2.20), but this
was not significant after permutation-based correction.
In men, no significant results were found (not shown).
Genotypic frequencies of the SNPs are shown in
Table 3. Results from the backward stepwise multiple
logistic regression, with the 3 SNPs and sex included in
the initial model, are shown in Table 4. Values for each
SNP were adjusted for the remaining significant vari-
ables in themodel. For themigraine sample, the TT geno-
type of rs941298 showed an increased risk in patients
with migraine (OR, 2.22; 95% CI, 1.19-4.12), signifi-
cant after Bonferroni correction; the GT and GG geno-
types of rs6951030 were also associated with an
increased risk of migraine (GT, OR, 1.68; 95% CI, 1.13-
2.51; GG, OR, 3.27; 95% CI, 1.35-7.88), also significant
after Bonferroni correction. Interestingly, the TT geno-
type of rs941298 also showed an increased risk of mi-
graine without aura (OR, 3.11; 95% CI, 1.52-6.33); and
heterozygosity for rs6951030 was associated with an in-
creased risk of migraine without aura (OR, 1.85; 95%CI,
1.14-2.99), withstanding Bonferroni correction. An OR
higher than 2 (OR, 3.01; 95% CI, 1.05-8.64) was found
for the GG genotype, whichmay indicate that this geno-
type is also a risk factor formigrainewithout aura (though
not statistically significant after Bonferroni correction),
similar to what was found in the sample of migraine with
aura (OR, 3.20; 95%CI, 1.14-8.92). The SNP rs3793243
did not show any significant association.
In a haplotype-based analysis (Table 5), C-C-G was
more frequent inmigraineurs than in controls (OR, 1.40,
but it did not withstand permutation-based correction).
Also, T-C-T was less frequent in migraineurs and in pa-
tients with migraine without aura than in controls, sug-
gesting a possible protective role of the T allele of
rs6951030 (migraine sample, OR, 0.54; P=.03; after a per-
mutation-based correction, OR, 0.43; P=.02). Interest-
ingly, we found an increased risk for the T-T-T haplo-
type in those with migraines without aura, showing that
the T allele of rs941298 might confer an increased risk
of migraines without aura (OR, 1.44), but this was not
significant after permutation-based correction.
We also stratified the haplotype-based analysis regard-
ing sex and found a protective role for T-C-T in women
(nonsignificant aftermultiple-testing correction). Inmen,
we did not find any differences in haplotype frequencies
between cases and controls (data not shown).
Patientswith cooccurrence ofmigraineswith andwith-
out aura were first included in the sample with aura. In
a further analysis, we decided to exclude these patients
from the analysis, and the results we found were similar
regarding the involvement of the 3 SNPs inmigrainewith
aura (data not shown).
Additionally, we performed a pooled analysis of our
data and those published by Corominas et al,12 exclud-
ing theCatalonian patients with hemiplegicmigraine.We
found a significant association between rs941298 and the
total sample and the group with migraine without aura
(not shown).With allele frequencies of rs941298 pooled
together, risk was significantly increased for the mi-
graine sample and in patients withmigraine without aura
who have the T allele (not shown). For rs6951030, we
did not find any significant results after pooling.
We performed a PupaSuite database search21 to as-
sess a putative functional role of these SNPs: (1) rs6951030
is located in a conserved region, which may indicate it
Table 1. Demographic and Clinical Data of Patients
With Migraine and Controls
Characteristic
No.
Patients
With Migraine
(n=188)
Controls
(n=287)
Migraine with aura 77
Migraine without aura 111
Sex, F/M 153/35 217/70
Age at observation, mean (SD), y 36.14 (12.84) 36.42 (12.35)
Age at onset, mean (SD), y 17.67 (8.15)
Family history of migraine, % 87
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Figure. Linkage disequilibrium plot of single-nucleotide polymorphisms
within STX1A (HaploView 4.1.); r 2 values are given within each square.
kb indicates kilobases.
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is important for gene regulation; and (2) rs941298 is lo-
cated in a triplex sequence and may affect its structure
formation, altering regulation. Additionally, we as-
sessed if there were any regulatory SNPs in LD with
rs6951030 and rs941298. The SNP rs6951030 is not in
LDwith any other SNP genotyped in theHapMap project.
We found that rs867500 (in LD with rs941298) is lo-
cated in an exonic-splicing enhancer motif.
COMMENT
We analyzed the role of STX1A in migraine susceptibil-
ity and, more specifically, in migraine subtypes with and
without aura. Our findings confirm the involvement of
STX1A as a risk factor for migraine. The intronic vari-
ants rs941298 and rs6951030 may play a role on mi-
graine and, particularly, in migraine without aura. Ad-
ditionally, we cannot exclude the effect of rs6951030 in
migraine with aura, because the homozygous state of GG
results in anOR above 2; however, the result was not sig-
nificant after Bonferroni correction.
The haplotype analysis also supports the involvement
of the rs6951030 G allele in migraine susceptibility and a
protective role for the T allele both for migraine and mi-
graine without aura. With this we also confirmed the in-
creased risk conferred by the rs941298 T allele. Compar-
ing allele frequencies,we foundanassociationof rs6951030
withmigraine andmigraine subtypes, while for rs941298
only an associationwithmigrainewithout aurawas found;
results for rs3793243 were not significant.
We found a sex-related effect in rs6951030, because
only the female group showed enrichment of the G al-
lele. This may be due to hormonal effects mediated by
epigenetic modifications.22 We cannot exclude, how-
ever, that the nonincreased risk inmen is due to its small
size in our sample. It would be important to explore this
in larger samples to disentangle a possible sex suscepti-
bility regarding syntaxin 1A.
In the recent study from Catalonia, Spain,12 signifi-
cant differences were found between cases and controls,
both in allele and genotype frequencies of rs941298. The
T allele was overrepresented in cases, either with or
without aura. In our study, we also found an effect of
the TT genotype in the global sample and in the subset
of migraine without aura. In contrast to our results, no
association with rs6951030 was found in the Catalonian
study.
Althoughour study replicates the involvementofSTX1A
in migraine susceptibility, different variants were associ-
ated. Our data suggest a stronger effect of this gene in mi-
graine without aura regarding rs6951030 and rs941298.
The difference between our results and those from
Catalonia12 regarding rs6951030may be due to allele fre-
Table 2. Allele Frequencies of SNPs Studied in Patients With Migraine and Controls
Participant
Alleles, No. (%)
2 OR (95% CI) P Value
P Value,
After PermutationT C G
rs3793243
All patients with migraine 159 (42.3) 217 (57.7) 0.00 1.00 (0.77-1.30) .99 1.00
Without aura 100 (45.0) 122 (55.0) 0.48 1.12 (0.82-1.52) .48 .97
With aura 59 (38.3) 95 (61.7) 0.81 0.85 (0.59-1.22) .37 .89
Controls 243 (42.3) 331 (57.7)
rs941298
All patients with migraine 130 (34.6) 246 (65.4) 2.05 1.22 (0.93-1.62) .15 .56
Without aura 85 (38.3) 137 (61.7) 4.85 1.44 (1.04-1.99) .03a .13
With aura 45 (29.2) 109 (70.8) 0.05 0.96 (0.65-1.41) .82 1.00
Controls 173 (30.1) 401 (69.9)
rs6951030
All patients with migraine 269 (71.5) 107 (28.5) 7.48 1.52 (1.12-2.06) .006a .03a
Without aura 160 (72.1) 62 (27.9) 4.72 1.48 (1.04-2.12) .03a .14
With aura 109 (70.8) 45 (29.2) 5.01 1.58 (1.06-2.36) .02a .12
Controls 455 (79.3) 119 (20.7)
Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
aNominal and corrected; significant value.
Table 3. Genotype Frequencies by Single-Nucleotide
Polymorphism in Patients With Migraine and Controls
Genotype
No. (%)
All Patients
With
Migraine
(n=188)
Patients With
Migraine
Controls
(n=287)
Without
Aura
(n=111)
With
Aura
(n=77)
rs3793243
CC 67 (35.6) 37 (33.3) 30 (39.0) 89 (31.0)
TC 83 (44.2) 48 (43.2) 35 (45.5) 153 (53.3)
TT 38 (20.2) 26 (23.4) 12 (15.6) 45 (15.7)
rs941298
CC 28 (14.9) 46 (41.4) 40 (51.9) 28 (9.8)
CT 74 (39.4) 45 (40.5) 29 (37.7) 117 (40.8)
TT 86 (45.7) 20 (18.0) 8 (10.4) 142 (49.5)
rs6951030
TT 95 (50.5) 56 (50.5) 39 (50.6) 178 (62.0)
TG 79 (42.0) 48 (43.2) 31 (40.3) 99 (34.5)
GG 14 (7.5) 7 (6.3) 7 (9.1) 10 (3.5)
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quency variation across populations; it may be more
marked owing to genegene and geneenvironment
interactions.23 This emphasizes the importance of repli-
cating association studies in several populations.
Additionally, when pooling both samples, we found
a significant effect of the T allele of rs941298 in mi-
graineurs; this was expected, as the Catalonian study
found significant results for this SNP and we saw an in-
creased risk with the TT genotype in our sample. These
results show that this SNP may be involved in suscepti-
bility to migraine in both populations. More impor-
tantly, we found an increased risk with the G allele of
rs6951030 inPortuguesemigraineurs,whichwasnot pres-
ent in the pooled sample; we can postulate that the as-
sociation with rs6951030 is specific to our population.
In FHM, glutamate release, facilitated by the mu-
tated voltage-dependent calcium channel1A subunit, re-
sults in cortical spreading depression (CSD), a slowly
propagating wave of neuronal and glial depolarization,
that moves through the cortex.24 Cortical spreading de-
pression is the underlying mechanism implicated in the
visual, sensory, or motor aura observed inmigraine with
aura, during which several neurotransmitters are re-
leased.24 In migraine without aura, imaging studies sug-
gest that CSD may occur in silent brain areas, leading to
pain but not other symptoms.25,26 The association of the
SNARE proteins (including syntaxin 1A) with presyn-
aptic Ca2 channels, namely the voltage-dependent cal-
cium channel 1A subunit, is essential for neurotrans-
mitter release.11 Therefore, polymorphisms in STX1Amay
alter the interaction between syntaxin 1A and calcium
channels, modifying the functional state of the voltage-
dependent calcium channel 1A, altering neurotransmit-
ter release and, ultimately, contributing to CSD and the
migraine phenotype.12,27
Although no functional role has yet been described
for any of these intronic SNPs, it would be important to
further evaluate that possibility. We found that both
rs941298 and rs6951030, but also rs867500 (which is
in LDwith rs941298), are located in regions that are po-
tentially important for regulation. Further analyses are
needed to evaluate a potential functional role of these SNPs
and understand their effect on syntaxin 1A.
Although our sample is not very large, we had spe-
cial concern in obtaining a high case to control ra-
tio—to increase power. Also, cases and controls were
matched for age at observation and sex and were from
the same geographic region (several studies, usingmark-
ers sensitive to population stratification as lineagemark-
ers, have shown that there is no population substruc-
Table 4. Results From the Backward Stepwise Multiple Logistic Regression
Genotype
Migraine Migraine Without Aura Migraine With Aura
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
rs3793243 .25 .30 .67
CCa 1 [Reference] 1 [Reference] 1 [Reference]
CT 0.66 (0.39-1.11) .12 0.62 (0.32-1.19) .15 0.80 (0.44-1.42) .44
TT 0.86 (0.38-1.94) .71 0.88 (0.33-2.34) .80 1.02 (0.46-2.29) .96
rs941298 .04 .008b .85
CCa 1 [Reference] 1 [Reference] 1 [Reference]
CT 1.16 (0.77-1.75) .48 1.32 (0.80-2.18) .27 1.16 (0.59-2.26) .67
TT 2.22 (1.19-4.12) .01b 3.11 (1.52-6.33) .002b 1.36 (0.42-4.45) .61
rs6951030 .004b .02b .06
TTa 1 [Reference] 1 [Reference] 1 [Reference]
GT 1.68 (1.13-2.51) .01b 1.85 (1.14-2.99) .01b 1.43 (0.84-2.43) .19
GG 3.27 (1.35-7.88) .008b 3.01 (1.05-8.64) .04 3.20 (1.14-8.92) .03
Abbreviations: CI, confidence interval; OR, odds ratio.
aAfter Bonferroni correction, significance level was set at =.016.
bSignificant value.
Table 5. Results From the Haplotype Analysis
Haplotypea
Cases Controls
OR (95% CI) 2 P Valueb
P Value,
After PermutationCarriers Noncarriers Carriers Noncarriers
All patients
C-C-G 89.9 286.1 105.4 468.6 1.40 (1.02-1.92) 4.28 .04c .17
T-C-T 30.8 345.2 81.7 492.3 0.54 (0.35-0.83) 7.94 .005c .03c
Patients with migraine without aura
T-C-T 14.9 207.1 81.7 492.3 0.43 (0.24-0.77) 8.49 .004c .02c
T-T-T 74.1 147.9 147.9 426.1 1.44 (1.03-2.02) 4.61 .03c .15
Abbreviations: CI, confidence interval; OR, odds ratio.
a rs3793243-rs941298-rs6951030.
bOnly haplotypes with any significant result are shown.
cNominal and corrected; significant value.
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ture among the Portuguese population28-30). Also, we used
corrections for multiple testing to prevent type I errors
(Bonferroni and permutation-based corrections).Weused
logistic regression analyses to examine the SNPs’ effects
altogether.
In conclusion, our study favors and brings new in-
sight into the involvement of syntaxin 1A in suscepti-
bility tomigraine and strengthens the role of neurotrans-
mitter release in its pathophysiology.We can thus confirm
the association between syntaxin 1A andmigraine found
in Catalonian patients. Additional studies with larger
samples in other populations will be important to dis-
entangle the role of this gene in migraine subtypes.
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To date, CSF analyses have not been a routine compo-
nent of assessment and care for patientswith cognitive im-
pairments and suspected AD in theUnited States. There is
now ample evidence that thesemeasurements have value;
physicians need to formulate when and how to incorpo-
rateCSFmeasurements into their practice.We strongly rec-
ommend CSF analyses of A1-42, T-tau, and P-tau in cir-
cumstances where having a definitive diagnosis of AD is
important for counseling patients about such concerns as
work, driving, andmakingother lifestyle changes. TheCSF
biomarkerswill also improveaccuracy fordetermining treat-
ment in clinical situationswhere other conditions, such as
normal-pressure hydrocephalus, depression, or vascular is-
chemic changes, figure in the differential diagnosis. There
is already ample evidence that the ADCSF signature has a
place in predicting which individuals with MCI are most
at risk to progress to dementia, and itmay even have value
in predicting the rate of cognitive decline. The CSF analy-
ses of A, T-tau, and P-tau should have a central place in
experimental clinical trials to increase the likelihood that
participants have AD and eliminate other diagnoses that
might dilute treatment effects.Gazing into the futurewhen
there are neuroprotective medications for AD, we can en-
vision a recommendation that CSF analyses be imple-
mented as a screening test to identify clinically healthy in-
dividuals at risk for MCI and AD. The information gained
would enable early application of treatments to delay on-
set of symptoms or slow progression of cognitive impair-
ments.
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Correction
Errors in Table. In the article “Evidence of Syntaxin 1A
Involvement in Migraine Susceptibility: A Portuguese
Study,” published in the April issue of theArchives (2010;
67[4]:422-427), there were a few errors in Table 3. In
the rs941298 section of the table, the CC and TT geno-
type cells in the “All Patients With Migraine” column
should be switched. The number and frequency for the
TT genotype should be 28 (14.9%) and for the CC geno-
type, 86 (45.7%). The CC and TT genotype cells should
also be switched in the “Controls” column: the number
and frequency for the TT genotype should be 28 (9.8%)
and for the CC genotype, 142 (49.5%).
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